2025-04-15 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Analysis

**0. Overview:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company providing a range of health benefits programs, services, and products.


**1. Performance Comparison and Divergence:**

UNH's cumulative return of 76.89% significantly outperforms the S&P 500 (VOO) with a cumulative return of 66.69%.  The difference is 10.2%, placing it at the 53.8th percentile of its historical range of divergence (max: 52.2%, min: -38.8%). This suggests UNH has shown relatively strong performance compared to the broader market, though not exceptionally so relative to its historical performance against the S&P 500.

Alpha and Beta Analysis:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 64.0% | 56.1% | 35.0% | 0.1 | 181.0 |
| 2016-2018  | 55.0% | 63.9% | 37.0% | 0.2 | 207.3 |
| 2017-2019  | 41.0% | 63.9% | 11.0% | 0.3 | 248.8 |
| 2018-2020  | -20.0% | 63.9% | -45.0% | 0.5 | 301.7 |
| 2019-2021  | 34.0% | 60.8% | -20.0% | 0.6 | 438.0 |
| 2020-2022  | 28.0% | 67.1% | 22.0% | 0.6 | 468.4 |
| 2021-2023  | 35.0% | 67.6% | 18.0% | 0.4 | 472.1 |
| 2022-2024  | -27.0% | 68.8% | -44.0% | 0.3 | 460.8 |
| 2023-2025  | 0.0% | 73.2% | -15.0% | 0.2 | 537.0 |

The data shows fluctuating CAGR and Alpha values, indicating varying performance relative to the market over time.  Beta is generally low, suggesting lower volatility than the market.  However, the provided Alpha values seem unusually high and inconsistent with the CAGR; further investigation into the calculation methodology is needed.


**2. Recent Price Movement:**

* **Closing Price:** $587.06
* **Previous Close:** $599.47
* **Change:** -$2.07 (a small decrease)
* **5-day Moving Average:** $582.50
* **20-day Moving Average:** $534.39
* **60-day Moving Average:** $515.29

The price is slightly below the 5-day moving average, suggesting recent minor downward pressure. However, it remains significantly above both the 20-day and 60-day moving averages, indicating a longer-term upward trend.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4585 (High Risk according to provided scale)
* **RSI:** 77.04 (Overbought territory, suggesting potential for a price correction)
* **PPO:** 1.43 (Positive, indicating bullish momentum)
* **20-day Relative Divergence Change:** +8.4% (Short-term upward trend)
* **Expected Return:** 11.8% (Long-term (2+ years) outperformance over S&P 500)

The high RSI suggests the stock might be overbought and prone to a short-term correction. However, the positive PPO and upward relative divergence indicate continued bullish momentum. The high MRI also warrants caution.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue           |
|------------|--------|-------------------|
| 2024-11-04 | 6.56   | $100.82 B        |
| 2024-08-09 | 4.58   | $98.86 B        |
| 2024-05-09 | -1.53  | $99.80 B        |
| 2023-11-06 | 6.31   | $92.36 B        |
| 2024-11-04 | 6.31   | $92.36 B        | *(Duplicate entry â€“ likely a data error)*

Revenue remains relatively consistent, but EPS shows significant volatility. The negative EPS in Q2 2024 is a concern requiring further investigation.  The duplicate entry for November 2024 needs clarification.


**5. Financial Information:**

Revenue and Profitability:

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |
| 2024-03-31 | $99.80B   | 23.05%        |
| 2023-12-31 | $94.43B   | 23.30%        |

Capital and Profitability:

| Quarter | Equity     | ROE    |
|---------|------------|--------|
| 2024-12-31 | $92.66B   | 5.98%  |
| 2024-09-30 | $94.53B   | 6.41%  |
| 2024-06-30 | $89.36B   | 4.72%  |
| 2024-03-31 | $86.69B   | -1.63% |
| 2023-12-31 | $88.76B   | 6.15%  |

Revenue remains strong and relatively stable.  Profit margins are healthy but show some fluctuation.  Equity is generally increasing, but ROE shows significant volatility, with a negative value in Q1 2024 mirroring the negative EPS.


**6. Overall Analysis:**

UNH has demonstrated strong historical outperformance compared to the S&P 500.  However, recent data indicates potential short-term risks. The high RSI, negative EPS and ROE in Q1 2024, and the high MRI suggest caution. The  significant volatility in earnings and ROE warrants further investigation into the underlying causes. Despite the strong long-term expected return, potential short-term corrections should be anticipated.  A more detailed analysis of the Q2 2024 negative EPS is crucial for a comprehensive assessment.  The discrepancies in the provided data (duplicate earnings entry, unusually high Alpha values) require clarification before making definitive conclusions.
